OBJECTIVE: To determine the effect of aspirin and anticoagulants on clinical outcomes and cause of in-hospital death in patients with nonvariceal upper gastrointestinal bleeding (NVUGIB). METHODS: Patients were identified from a tertiary center database that included all patients with UGIB. Clinical outcomes including (1) in-hospital mortality, (2) severe bleeding, (3) rebleeding, (4) in-hospital complications, and (5) length of hospital stay were examined in patients taking (a) aspirin only, (b) anticoagulants only, and (c) no antithrombotics. RESULTS: Of 717 patients with NVUGIB, 56 % (402) were taking at least one antithrombotic agent. Seventy-eight (11 %) patients died in hospital, and 310 (43 %) had severe bleeding (BP < 90 mmHg, HR > 120 b/min, Hb < 7 g/dL on presentation, or transfusion of >3 units). On multivariate analysis, being on aspirin was protective against in-hospital mortality [OR 0.26 (0.13-0.53)], rebleeding [OR 0.31 (0.17-0.59)], and predictive of a shorter hospital stay (coefficient = -4.2 days; 95 % CI -8.7, 0.3). Similarly, being on nonaspirin antiplatelets was protective against in-hospital mortality (P = 0.03). However, being on anticoagulants was predictive of in-hospital complications [OR 2.0 (1.20-3.35)] and severe bleeding [OR 1.69 (1.02-2.82)]. Compared to those not taking any antithrombotics, patients who bled on aspirin were less likely to die in hospital of uncontrolled gastrointestinal bleeding (3.6 vs 0 %, P ≤ 0.01) and systemic cancer (4.9 vs 0 %, P ≤ 0.002), but equally likely to die of cardiovascular/thromboembolic disease, sepsis, and multiorgan failure. CONCLUSION: Patients who present with NVUGIB on aspirin had reduced in-hospital mortality and fewer adverse outcomes, while those on anticoagulants had increased in-hospital complications.
OBJECTIVE: To determine the effect of aspirin and anticoagulants on clinical outcomes and cause of in-hospital death in patients with nonvariceal upper gastrointestinal bleeding (NVUGIB). METHODS:Patients were identified from a tertiary center database that included all patients with UGIB. Clinical outcomes including (1) in-hospital mortality, (2) severe bleeding, (3) rebleeding, (4) in-hospital complications, and (5) length of hospital stay were examined in patients taking (a) aspirin only, (b) anticoagulants only, and (c) no antithrombotics. RESULTS: Of 717 patients with NVUGIB, 56 % (402) were taking at least one antithrombotic agent. Seventy-eight (11 %) patients died in hospital, and 310 (43 %) had severe bleeding (BP < 90 mmHg, HR > 120 b/min, Hb < 7 g/dL on presentation, or transfusion of >3 units). On multivariate analysis, being on aspirin was protective against in-hospital mortality [OR 0.26 (0.13-0.53)], rebleeding [OR 0.31 (0.17-0.59)], and predictive of a shorter hospital stay (coefficient = -4.2 days; 95 % CI -8.7, 0.3). Similarly, being on nonaspirin antiplatelets was protective against in-hospital mortality (P = 0.03). However, being on anticoagulants was predictive of in-hospital complications [OR 2.0 (1.20-3.35)] and severe bleeding [OR 1.69 (1.02-2.82)]. Compared to those not taking any antithrombotics, patients who bled on aspirin were less likely to die in hospital of uncontrolled gastrointestinal bleeding (3.6 vs 0 %, P ≤ 0.01) and systemic cancer (4.9 vs 0 %, P ≤ 0.002), but equally likely to die of cardiovascular/thromboembolic disease, sepsis, and multiorgan failure. CONCLUSION:Patients who present with NVUGIB on aspirin had reduced in-hospital mortality and fewer adverse outcomes, while those on anticoagulants had increased in-hospital complications.
Authors: A Lanas; L Aabakken; J Fonseca; Z A Mungan; G V Papatheodoridis; H Piessevaux; L Cipolletta; J Nuevo; M Tafalla Journal: Aliment Pharmacol Ther Date: 2011-04-11 Impact factor: 8.171
Authors: H T Sørensen; L Mellemkjaer; W J Blot; G L Nielsen; F H Steffensen; J K McLaughlin; J H Olsen Journal: Am J Gastroenterol Date: 2000-09 Impact factor: 10.864
Authors: Alan N Barkun; Marc Bardou; Ernst J Kuipers; Joseph Sung; Richard H Hunt; Myriam Martel; Paul Sinclair Journal: Ann Intern Med Date: 2010-01-19 Impact factor: 25.391
Authors: B Joseph Elmunzer; Scott D Young; John M Inadomi; Philip Schoenfeld; Loren Laine Journal: Am J Gastroenterol Date: 2008-08-05 Impact factor: 10.864
Authors: Joseph J Y Sung; Kelvin K F Tsoi; Terry K W Ma; Man-Yee Yung; James Y W Lau; Philip W Y Chiu Journal: Am J Gastroenterol Date: 2009-09-15 Impact factor: 10.864
Authors: Hussein Abu Daya; Mohamad Eloubeidi; Hani Tamim; Houssam Halawi; Ahmad H Malli; Don C Rockey; Kassem Barada Journal: J Dig Dis Date: 2014-06 Impact factor: 2.325
Authors: Peter C Elwood; Gareth Morgan; Janet E Pickering; Julieta Galante; Alison L Weightman; Delyth Morris; Mark Kelson; Sunil Dolwani Journal: PLoS One Date: 2016-04-20 Impact factor: 3.240
Authors: Peter C Elwood; Gareth Morgan; Julieta Galante; John W K Chia; Sunil Dolwani; J Michael Graziano; Mark Kelson; Angel Lanas; Marcus Longley; Ceri J Phillips; Janet Pickering; Stephen E Roberts; Swee S Soon; Will Steward; Delyth Morris; Alison L Weightman Journal: PLoS One Date: 2016-11-15 Impact factor: 3.240